Article (Scientific journals)
Imatinib and Nilotinib Inhibit Hematopoietic Progenitor Cell Growth, but Do Not Prevent Adhesion, Migration and Engraftment of Human Cord Blood CD34+ Cells
Belle, Ludovic; Bruck, France; FOGUENNE, Jacques et al.
2012In PLoS ONE, 7 (12), p. 52564
Peer Reviewed verified by ORBi
 

Files


Full Text
PlosOne_Belle_TKIs-Hematopoiesis.pdf
Publisher postprint (521.26 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Tyrosine kinase inhibitors; Allogeneic stem cell transplantation; Engraftment
Abstract :
[en] Background: The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia. The BCR-ABL inhibitor imatinib is also known to inhibit the tyrosine kinase of the stem cell factor receptor, c-Kit. Nilotinib is 30 times more potent than imatinib towards BCR-ABL in vitro. Studies in healthy volunteers and patients with chronic myelogenous leukemia or gastrointestinal stromal tumors have shown that therapeutic doses of nilotinib deliver drug levels similar to those of imatinib. The aim of this study was to compare the inhibitory effects of imatinib and nilotinib on proliferation, differentiation, adhesion, migration and engraftment capacities of human cord blood CD34+ cells. Design and Methods: After a 48-hour cell culture with or without TKIs, CFC, LTC-IC, migration, adhesion and cell cycle analysis were performed. In a second time, the impact of these TKIs on engraftment was assessed in a xenotransplantation model using NOD/SCID/IL-2Rc (null) mice. <br />Results: TKIs did not affect LTC-IC frequencies despite in vitro inhibition of CFC formation due to inhibition of CD34+ cell cycle entry. Adhesion of CD34+ cells to retronectin was reduced in the presence of either imatinib or nilotinib but only at high concentrations. Migration through a SDF-1a gradient was not changed by cell culture in the presence of TKIs. Finally, bone marrow cellularity and human chimerism were not affected by daily doses of imatinib and nilotinib in a xenogenic transplantation model. No significant difference was seen between TKIs given the equivalent affinity of imatinib and nilotinib for KIT. <br />Conclusions: These data suggest that combining non-myeloablative conditioning regimen with TKIs starting the day of the transplantation could be safe.
Research center :
GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège
Disciplines :
Hematology
Author, co-author :
Belle, Ludovic ;  Université de Liège - ULiège > GIGA-R : Hématologie
Bruck, France
FOGUENNE, Jacques ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
GOTHOT, André ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
BEGUIN, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Baron, Frédéric  ;  Université de Liège - ULiège > GIGA-R : Hématologie
Briquet, Alexandra ;  Université de Liège - ULiège > GIGA-R : Hématologie
Language :
English
Title :
Imatinib and Nilotinib Inhibit Hematopoietic Progenitor Cell Growth, but Do Not Prevent Adhesion, Migration and Engraftment of Human Cord Blood CD34+ Cells
Publication date :
2012
Journal title :
PLoS ONE
eISSN :
1932-6203
Publisher :
Public Library of Science, San Franscisco, United States - California
Volume :
7
Issue :
12
Pages :
e52564
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Available on ORBi :
since 21 January 2013

Statistics


Number of views
82 (21 by ULiège)
Number of downloads
137 (2 by ULiège)

Scopus citations®
 
6
Scopus citations®
without self-citations
5
OpenCitations
 
6

Bibliography


Similar publications



Contact ORBi